Background

The present study aimed to assess the clinical features of patients who received lenvatinib treatment for unresectable hepatocellular carcinoma (HCC).

Methods

The clinical characteristics, adverse events, and radiological responses were evaluated for 51 consecutive patients.

Results

Of the study subjects, 37 patients had Child–Pugh class A (CPA) liver function, and 14 patients had Child–Pugh class B (CPB) liver function. The overall response rates in the CPA and CPB groups were 42.9% and 25.0%, respectively, and disease control rates were 82.9% and 83.3%, respectively, without significant difference (p = 0.2621 and 0.9697). There was no significant difference between CPA and CPB groups regarding the incidence of adverse events, except for hepatic coma. No significant difference was observed in the relative dose intensity between the CPA and CPB groups, for the first month, 1–2 months, or 2–3 months (p = 0.2368, 0.9368, and 0.9293).

Conclusion

The comparable outcomes between the CPA and CPB groups suggest the acceptability of lenvatinib treatment in patients with impaired liver function, at least in the acute phase. With careful follow-up, the dose can be relatively intensified, even in patients with impaired liver function and this may contribute to offering comparable treatment.

中文翻译：

---

乐伐替尼治疗不可切除的肝细胞癌伴肝硬化的评估

背景

本研究旨在评估接受乐伐替尼治疗的不可切除肝细胞癌 (HCC) 患者的临床特征。

方法

对 51 名连续患者的临床特征、不良事件和放射学反应进行了评估。

结果

在研究对象中，37 名患者具有 Child-Pugh A 级 (CPA) 肝功能，14 名患者具有 Child-Pugh B 级 (CPB) 肝功能。CPA和CPB组的总体反应率分别为42.9%和25.0%，疾病控制率分别为82.9%和83.3%，无显着差异（p=0.2621和0.9697）。除了肝昏迷外，CPA 和 CPB 组在不良事件发生率方面没有显着差异。在第一个月、1-2 个月或 2-3 个月，CPA 和 CPB 组之间的相对剂量强度没有观察到显着差异（p = 0.2368、0.9368 和 0.9293）。

结论

CPA 和 CPB 组之间的可比结果表明乐伐替尼治疗肝功能受损患者的可接受性，至少在急性期。通过仔细的随访，即使在肝功能受损的患者中，剂量也可以相对增加，这可能有助于提供类似的治疗。